CIK 0001814390
CORFX Flat Rock Core Income Fund
Insider trading from SEC Form 4. Last filing Dec 11, 2025. Close $19.02 on Oct 9, 2026, +5% from the 52-week low and 0% from the high.
Flat Rock Core Income Fund (CORFX) has 6 SEC Form 4 filings on file from 3 insiders, the latest filed on Dec 11, 2025. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
6 open-market trades have been scored at CORFX. The newest: R. Scott Coolidge (director) bought $25k of stock on Dec 9, 2025, filed Dec 11, 2025, scored 55 (moderate). 3 insiders bought within 14 days of each other around Dec 9, 2025.
CORFX closed at $19.02 on Oct 9, 2026, 5% above its 52-week low and at a 52-week high.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Flat Rock Core Income Fund, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 55Moderate | R. Scott Coolidge director buy | $25k 1,262 shares | +70% | +6% from low0% from high | |
| 55Moderate | Marshall Durston director buy | $25k 1,262 shares | +70% | +6% from low0% from high | |
| 55Moderate | Paul E. Finnen director buy | $25k 1,262 shares | +70% | +6% from low0% from high | |
| 36Weak | R. Scott Coolidge director buy | $10k 488 shares | +42% | - | |
| 36Weak | Marshall Durston director buy | $10k 488 shares | +42% | - | |
| 36Weak | Paul E. Finnen director buy | $10k 488 shares | +42% | - |
Transactions
Every row filed, 6 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 9, 2025 | R. Scott Coolidge director | POpen-market purchase Common Shares of Beneficial Interest | +1,262 | $19.81 | $25k | 3,063 | Dec 11, 2025 |
| Dec 9, 2025 | Marshall Durston director | POpen-market purchase Common Shares of Beneficial Interest | +1,262 | $19.81 | $25k | 3,063 | Dec 11, 2025 |
| Dec 9, 2025 | Paul E. Finnen director | POpen-market purchase Common Shares of Beneficial Interest | +1,262 | $19.81 | $25k | 3,063 | Dec 11, 2025 |
| Dec 18, 2024 | R. Scott Coolidge director | POpen-market purchase Common Shares of Beneficial Interest | +488 | $20.51 | $10k | 1,645 | Dec 20, 2024 |
| Dec 18, 2024 | Marshall Durston director | POpen-market purchase Common Shares of Beneficial Interest | +488 | $20.51 | $10k | 1,645 | Dec 20, 2024 |
| Dec 18, 2024 | Paul E. Finnen director | POpen-market purchase Common Shares of Beneficial Interest | +488 | $20.51 | $10k | 1,645 | Dec 20, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- R. Scott Coolidgedirector
- Marshall Durstondirector
- Paul E. Finnendirector
Questions about CORFX
Answered from the filings on this page, as of the latest one.
Are insiders buying CORFX?
No. In the last 90 days no insider at Flat Rock Core Income Fund bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade CORFX on the open market?
R. Scott Coolidge (director) bought $25k of CORFX on Dec 9, 2025 and filed the Form 4 on Dec 11, 2025. InsiderTell scored 55 (moderate), with 3 insiders on the same side within 14 days.
How many insiders file Form 4 at Flat Rock Core Income Fund?
3 people have filed a Form 4 at Flat Rock Core Income Fund, among them R. Scott Coolidge (director), Marshall Durston (director), Paul E. Finnen (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.